← Kamada Ltd. (KMDA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Kamada Ltd. (KMDA)
Pharmaceutical Preparations · market cap $504M · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
12
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Kamada Ltd. (KMDA) is an Israeli plasma-derived biopharmaceutical company with 6 FDA-approved products distributed across 30+ international markets and a deep pipeline centered on Alpha-1 Antitrypsin (AAT) across multiple indications. At a $415M market cap with 450 employees, the company is a focused specialty plasma player with the nearest binary event being Q3 2026 earnings on August 12. Analyst consensus price targets range $11–$15 against a current price of ~$7.49, implying meaningful upside if pipeline milestones convert.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Kamada-AAT for Inhalation, 80mg | Phase 2 | Alpha-1 Antitrypsin Deficiency |
| Alpha 1-Antitrypsin | Phase 3 | Alpha 1-Antitrypsin Deficiency |
| KamRAB - HRIG | Phase 3 | Rabies |
| GLASSIA® and Institution standard of care (SOC) | Phase 2 | Transplantation, Lung Rejection |
| Alpha-1 Antitrypsin | Phase 2 | New Onset Type-1 Diabetes |
| Aerosolized, human, plasma-derived Alpha-1 Antitrypsin | Phase 2 | Cystic Fibrosis |
| Active rabies vaccine (US-FDA approved) | Phase 3 | Rabies |
| Kamada Anti-SARS-CoV-2 | Phase 2 | Covid19 |
| Alpha-1 Antitrypsin 40mg (AAT, Glassia®) | Phase 2 | Type 1 Diabetes Mellitus |
| Kamada AAT for inhalation | Phase 3 | Emphysema |
| Kamada-API | Phase 3 | Alpha 1-Antitrypsin Deficiency |
| AAT( Alpha 1 Antitrypsin) | Phase 2 | Type 1 Diabetes |
Price & technical context
3-month
+9.3%
6-month
-3.2%
12-month
+18.2%
52-wk range
$6.60–$9.31
vs 50-day MA
+3.2%
vs 200-day MA
+2.9%
Realized vol
34.7%
Max drawdown
-30.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KMDA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.